

## Anti-MLH1

Catalog No.	Description
AM703-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AM703-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
MU703-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
MU703-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AX703-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 160 tests
AX703-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 50 tests
AX703-4M	Ready-to-Use Antibody in Barcode labeled vial for use on the NanoVIP® Staining System, 50 tests
VM703-5M	6 ml of Ready-to-Use Antibody for use with BioGenex / equivalent Detection systems on third party automation.

Clone	Species	Ig Class
ES05	Mouse	IgG1

### Intended Use

**For In Vitro Diagnostic Use.** This antibody is designed for the specific localization of human MLH1 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

### Summary and Explanation

MLH1, a mismatch repair protein involved in maintaining the integrity of genetic information, alongside MSH2, MSH6 and PMS2. During DNA replication, strand misalignment can occur resulting in alterations to microsatellite repeats, often referred to as microsatellite instability (MSI). Mutations in the MLH1 gene have been reported to be found in tumors with MSI, such as some forms of colon cancer e.g. Hereditary nonpolyposis colon cancer (HNPCC), a subset of sporadic carcinomas and breast cancer. Loss of expression of MLH1 has also been reported in acute lymphoblastic leukemia, endometrial carcinoma, Gastric carcinoma and ovarian carcinoma.

### Storage and Handling

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

### Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

### Reagents Provided

Mouse Monoclonal Antibody to human MLH1 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

### Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

### Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	COLON as available from BioGenex FB-703M* & FG-703M*
Recommended Dilution for Concentrated Antibody	<b>1: 20-50 in HK941</b>
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment (Xmatrx & NanoVIP)	EZ-AR2 Elegance (HX032-YCD & HX046-08XN)
Antibody Incubation (Manual/i6000)	30-60 mins at RT
Antibody Incubation (Xmatrx & NanoVIP)	30-60 mins at 25°C
Detection System for Manual, Xmatrx, NanoVIP & i6000 systems***	Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

Category	Antibodies	Revision No.	K
Document No.	932-703M-EN	Release Date	27-May-2025

\*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx & NanoVIP requires micro chamber slides.

\*\*Pretreatment times will vary based on individual microwave power.

\*\*\*For automation systems (Xmatrx-Elite, NanoVIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKEN (1000 Test)		
	QD420-YIKEN (500 Test)	QD620-XAKEN (500 Test)	QP900-9LE (500 Test)
	QD400-60KEN (60 Test)		
Xmatrx - Automation	QD550-YCDEN (200 Test)	QD610-YADEN (200 Test)	N/A
NanoVIP- Automation	QD551-YCDEN (100 Test)	QD611-YADEN (100 Test)	N/A
i6000 - Automation	QD410-YAXEN (200 Test)	QD610-YAXEN (200 Test)	N/A
For more information, visit <a href="http://www.biogenex.com">www.biogenex.com</a> .			

### Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

### Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

### Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or [support@biogenex.com](mailto:support@biogenex.com) or your local distributor to report unusual staining.

### Expected Results

This antibody stains nucleus in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product

page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

### Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

### Bibliography

1. National committee for clinical Laboratory standards (NCCLS), Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova P.A. 1991;7(79). Order code M29-P
2. Battifora H. Diagnostic uses of antibodies to keratins: a review and immunohistochemical comparison of seven monoclonal and three polyclonal antibodies. Progress in Surgical Pathology. 6:1-15. Eds. Fenoglio-Preiser C, Woff CM, Rike F. Field and Wood, Inc. Philadelphia.
3. Omata M. Liew CT, Aschavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a possible source of error in immunohistochemistry. American Journal of Clinical Pathology. 1980; 73:626

	Temperature Limitation		In Vitro Diagnostic Medical Device
	Use By Date		Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	K
Document No.	932-703M-EN	Release Date	27-May-2025